CoChat

Validation of Rat Endometriosis Model by Using Raloxifene as a Positive Control for the Evaluation of Novel SERM Compounds

Yao, Z., Shen, X., Capodanno, I., Donnelly, M., Fenyk-Melody, J., Hausamann, J., Nunes, C., Strauss, J., Vakerich, K. · 2005 · Journal of Investigative Surgery

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Approximately 10% of women of reproductive age suffer from endometriosis, a potentially painful disease process and important cause of female infertility. Raloxifene, a commercially available SERM (selective estrogen receptor modulator) compound, used for the treatment of postmenopausal osteoporosis, has preclinically demonstrated its estrogen antagonist effect on uterine tissue in rats. There is potential that SERM compounds may become a viable treatment option for human endometriosis, although more investigation is needed. In this study, raloxifene was administered at various doses to determine the efficacy and an appropriate dose level for use as a positive control in a rat model of endometriosis. Prior to dose administration, all rats underwent a bilateral ovariectomy, autologous transplantation of uterine tissue onto the peritoneal surface of the abdominal wall, and implantation of a subcutaneous estrogen pellet (E2). Two separate postsurgical experiments were performed. In experiment 1, following a 4-wk recovery, the rats bearing implants were assigned to three groups: (1) removal of the E2 pellet and dosing vehicle only (n = 7); (2) E2 and vehicle (n = 6); and (3) E2 and raloxifene at 10.0 mg/kg (n = 6). In experiment 2, also following a 4-week recovery, the rats bearing implants were assigned to five groups (n = 8/group): (1) E2 and vehicle only; (2) E2 and raloxifene, 0.3 mg/kg/d; (3) E2 and raloxifene, 1.0 mg/kg/d; (4) E2 and raloxifene, 3.0 mg/kg/d; (5) E2 and raloxifene, 10.0 mg/kg/d. All rats were dosed orally BID for 14 d. At the end of the study, the implanted endometrium was remeasured and compared to the pretreatment measurement. The results from both studies demonstrated that Raloxifene at only one dose (10.0 mg/kg) displayed significant implant regression (p < .05). Subsequently, our rat endometriosis experimental model consistently uses the exogenous E2 pellet and raloxifene at 10 mg/kg, BID, as a positive control to help screen and compare novel SERM compounds.

Overview

Integrity signals

Registry

Crossref · 10.1080/08941930591004412

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 9 references

Research works printed but not linked: 2

  1. Littman B A, 1995, Principles and Practice of Endocrinology and metabolism, 2nd ed., 906
  2. Okada H, 1987, J Pharmacol Exp Ther, 244, 744

Cited by

See all 60

Metadata

Authors
Yao, Z., Shen, X., Capodanno, I., Donnelly, M., Fenyk-Melody, J., Hausamann, J., Nunes, C., Strauss, J., & Vakerich, K.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Venue
Journal of Investigative Surgery
Published
2005-01
Volume
18
Issue
4
Pages
177-183
ISSN
  • 0894-1939 (ISSN-L)
  • 1521-0553
OpenAlex
W1965260226
Cited by
60
References
9
Citations by year
2024: 3 · 2023: 3 · 2022: 4 · 2021: 6 · 2019: 5 · 2018: 7 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 5 · 2013: 2 · 2012: 4
FWCI
3.50
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Investigative Surgery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Effects and risks of endocrine disrupting chemicals
Keywords
endometriosis, rat endometriosis model, raloxifene, selective estrogen receptor modulators, positive control, dose selection, drug screening, female infertility, antiestrogens, ovariectomy, estrogen receptor antagonism, endometriosis treatment
MeSH terms
Animals, Disease Models, Animal, Endometriosis, Endometrium, Female, Organ Size, Rats, Sprague-Dawley, Selective Estrogen Receptor Modulators, Raloxifene Hydrochloride, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Validation of Rat Endometriosis Model by Using Raloxifene as a Positive Control for the Evaluation of Novel SERM Compounds. https://app.cochat.ai/papers/10.1080/08941930591004412
The paper
Yao, Z., Shen, X., Capodanno, I., Donnelly, M., Fenyk-Melody, J., Hausamann, J., Nunes, C., Strauss, J., & Vakerich, K. (2005). Validation of Rat Endometriosis Model by Using Raloxifene as a Positive Control for the Evaluation of Novel SERM Compounds. Journal of Investigative Surgery. https://doi.org/10.1080/08941930591004412

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.